• Product nameAnti-CBL (phospho Y674) antibody
    See all CBL primary antibodies
  • Description
    Rabbit polyclonal to CBL (phospho Y674)
  • SpecificityBinds CBL only when phosphorylated at these sites: Human: Tyr674; Mouse: Tyr672; Rat: Tyr780
  • Tested applicationsSuitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthesized phosphopeptide derived from human CBL around the phosphorylation site of tyrosine 674 (A-I-YP-S-L).

  • Positive control
    • HepG2 cells extract
  • General notesStable at -20°C for 1 year


Associated products


Our Abpromise guarantee covers the use of ab58508 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 99 kDa.
ELISA 1/5000.


  • FunctionParticipates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
  • PathwayProtein modification; protein ubiquitination.
  • Involvement in diseaseDefects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
  • Sequence similaritiesContains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
    Contains 1 RING-type zinc finger.
    Contains 1 UBA domain.
  • DomainThe RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
    The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
  • Post-translational
    Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
  • Cellular localizationCytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • 4732447J05Rik antibody
    • C CBL antibody
    • Cas Br M (murine) ecotropic retroviral transforming sequence antibody
    • Casitas B lineage lymphoma proto oncogene antibody
    • Casitas B-lineage lymphoma proto-oncogene antibody
    • CBL 2 antibody
    • cbl antibody
    • CBL_HUMAN antibody
    • CBL2 antibody
    • E3 ubiquitin protein ligase CBL antibody
    • E3 ubiquitin-protein ligase CBL antibody
    • Oncogene CBL2 antibody
    • Proto oncogene c CBL antibody
    • Proto-oncogene c-CBL antibody
    • RGD1561386 antibody
    • RING finger protein 55 antibody
    • RNF55 antibody
    • Signal transduction protein CBL antibody
    see all

Anti-CBL (phospho Y674) antibody images

  • All lanes : Anti-CBL (phospho Y674) antibody (ab58508) at 1/500 dilution

    Lane 1 : Extracts from HepG2 cells, treated with Na2VO3 (0.3nM, 40mins)
    Lane 2 : Extracts from HepG2 cells, treated with Na2VO3 (0.3nM, 40mins), plus immunising peptide

    Predicted band size : 99 kDa

References for Anti-CBL (phospho Y674) antibody (ab58508)

This product has been referenced in:
  • Fernandes MS  et al. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 285:32596-605 (2010). WB . Read more (PubMed: 20622007) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab58508.
Please use the links above to contact us or submit feedback about this product.